NEWS RELEASE

Anti-Tau Antibody created by Teijin Pharma and developed byMerck & Co., Inc., Kenilworth NJ USAEnters Clinical Development
Tokyo, Japan, February 1, 2022 --- Teijin Pharma Limited, the core company of theTeijin Group’s healthcare business, announced today that Merck & Co., Inc., Kenilworth,NJ, USA, a leading global biopharmaceutical company (known as MSD outside the U.S.
and Canada), has initiated a clinical trial of an antibody candidate targeting tau being
developed under license from Teijin Pharma. Teijin Pharma has received a milestone
payment from Merck & Co., Inc., Kenilworth, NJ USA.
The anti-tau antibody, which Teijin Pharma created is designed specifically to bind toabnormally hyperphosphorylated tau proteins.
The number of dementia patients worldwide is predicted to rise to nearly 76 million in
2030 and then to 139 million in 2050, according to research performed by Alzheimer'sDisease International. Two pathological changes in the brain are considered to be thecause of Alzheimer’s disease: the extracellular deposition of amyloid β peptide andneurofibrillary tangles resulting from intracellular accumulation of hyperphosphorylatedtau proteins.
Teijin Pharma and Merck & Co., Inc., Kenilworth, NJ USA signed a license agreement inMay 2017 under which Merck & Co., Inc., Kenilworth, NJ USA has exclusive worldwide
rights to develop, manufacture and commercialize Teijin Pharma’s anti-tau antibody. Inexchange, Teijin Pharma received an upfront payment and is eligible to receive
development, regulatory and sales milestone payments as well as royalties on any
product sales. Teijin Pharma also retains an option to co-promote an approved productin Japan.
The agreement with Merck & Co., Inc., Kenilworth, NJ USA is one of many alliances thatTeijin Pharma has entered for products that the company has developed in-house withthe aim of realizing innovative and effective treatments to enhance the quality of life ofpatients. Merck & Co., Inc., Kenilworth, NJ USA’s strong neuroscience expertise makes
it well suited to maximize the potential of this antibody candidate.
About the Teijin Group
Teijin (TSE: 3401) is a technology-driven global group offering advanced solutions in thefields of environmental value; safety, security and disaster mitigation; and demographic
change and increased health consciousness. Originally established as Japan's firstrayon manufacturer in 1918, Teijin has evolved into a unique enterprise encompassing
three core business domains: high-performance materials including aramid, carbon

fibers and composites, and also resin and plastic processing, films, polyester fibers andproducts converting; healthcare including pharmaceuticals and home healthcare
equipment for bone/joint, respiratory and cardiovascular/metabolic diseases, nursing
care and pre-symptomatic healthcare; and IT including B2B solutions for medical,
corporate and public systems as well as packaged software and B2C online services for
digital entertainment. Deeply committed to its stakeholders, as expressed in the brandstatement “Human Chemistry, Human Solutions,” Teijin aims to be a company that
supports the society of the future. The group comprises more than 170 companies andemploys some 20,000 people across 20 countries worldwide. Teijin posted consolidated
sales of JPY 836.5 billion (USD 7.7 billion) and total assets of JPY 1,036.4 billion (USD9.5 billion) in the fiscal year that ended on March 31, 2021.
Press Contact
Corporate Communications
Teijin Limited
pr@teijin.co.jp